NCT02517307View on ClinicalTrials.gov

Fatty Acid Oxidation Defects and Insulin Sensitivity

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

January 31, 2021

Study Completion Date

March 31, 2021

Conditions
Very Long-chain Acyl-CoA Dehydrogenase DeficiencyTrifunctional Protein DeficiencyLong-chain 3-hydroxyacyl-CoA Dehydrogenase DeficiencyMedium-chain Acyl-CoA Dehydrogenase DeficiencyNormal VolunteersCarnitine Palmitoyltransferase II Deficiency, Myopathic
Interventions
DRUG

Intralipid/Heparin

Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp

DRUG

Glycerol/Saline

Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp

DRUG

Hyperinsulinemic euglycemic clamp

Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.

Trial Locations (1)

97239

Oregon Health & Science University, Portland

All Listed Sponsors
lead

Oregon Health and Science University

OTHER

NCT02517307 - Fatty Acid Oxidation Defects and Insulin Sensitivity | Biotech Hunter | Biotech Hunter